Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Clinical Pharmacokinetics
|
January 10, 2017
Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection
Phyllis Chan, Hanbin Li, Li Zhu, et al.
Cancer Chemotherapy and Pharmacology
|
March 7, 2024
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
Colby S Shemesh, Yongsheng Wang, Andrew An, et al.
Clinical Pharmacology and Therapeutics
|
May 22, 2023
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 16, 2021
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, et al.
Infectious Diseases and Therapy
|
March 29, 2018
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
Li Zhu, Hanbin Li, Phyllis Chan, et al.
Cancer Chemotherapy and Pharmacology
|
September 23, 2019
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
Kari M Morrissey, Mathilde Marchand, Hina Patel, et al.
Pharmacology Research & Perspectives
|
November 26, 2020
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden
Colby S Shemesh, Phyllis Chan, Fatema A Legrand, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 5, 2025
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer
Phyllis Chan, Stephanie N Liu, Nathalie Gosselin, et al.
Frontiers in Pharmacology
|
October 13, 2022
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
Weize Huang, Felix Stader, Phyllis Chan, et al.
Clinical and Translational Science
|
August 25, 2021
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Benjamin Wu, Nitzan Sternheim, Priya Agarwal, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Clinical Pharmacokinetics
|
January 10, 2017
Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection
Phyllis Chan, Hanbin Li, Li Zhu, et al.
Cancer Chemotherapy and Pharmacology
|
March 7, 2024
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
Colby S Shemesh, Yongsheng Wang, Andrew An, et al.
Clinical Pharmacology and Therapeutics
|
May 22, 2023
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 16, 2021
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, et al.
Infectious Diseases and Therapy
|
March 29, 2018
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
Li Zhu, Hanbin Li, Phyllis Chan, et al.
Cancer Chemotherapy and Pharmacology
|
September 23, 2019
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
Kari M Morrissey, Mathilde Marchand, Hina Patel, et al.
Pharmacology Research & Perspectives
|
November 26, 2020
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden
Colby S Shemesh, Phyllis Chan, Fatema A Legrand, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 5, 2025
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer
Phyllis Chan, Stephanie N Liu, Nathalie Gosselin, et al.
Frontiers in Pharmacology
|
October 13, 2022
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
Weize Huang, Felix Stader, Phyllis Chan, et al.
Clinical and Translational Science
|
August 25, 2021
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Benjamin Wu, Nitzan Sternheim, Priya Agarwal, et al.
Page
of 4